Drug intelligence / Profile preview

TB-Bs1

Development stage: Preclinical
Lead developer: Traverse Biotech
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TB-Bs1 is a bispecific antibody being developed by Traverse Biotech in collaboration with Genmab. It utilizes Genmab's DuoBody platform to function as a T-cell engager, simultaneously targeting CD3 on T cells and Receptor Tyrosine Kinase Like Orphan Receptor 2 (ROR2) on tumor cells. By bridging these two cell types, TB-Bs1 facilitates the recruitment and activation of cytotoxic T cells to specifically eliminate ROR2-positive solid tumor cells. The program is currently in the early stages of development for the treatment of various ROR2-expressing solid malignancies.

Targets

ROR2CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on TB-Bs1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TB-Bs1.

Explore the full profile